secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-01-26T23:59:59+00:00
Accession:  0001193125-24-016715
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology raises $150M via oversubscribed private placement at 29% premium
------------------------------------------------------------------------------

- $150M gross proceeds from sale of 1.38M shares and 7.32M pre-funded warrants at $17.25/share.
- 29% premium to Jan 23 close; lead investors include EcoR1 Capital, Deerfield affiliate, Suvretta Capital.
- Pro forma cash, equivalents, and investments expected to fund operations into 2027.
- Net proceeds to support R&D for clinical-stage candidates and general corporate purposes.
- Virtual investor event on Jan 30 to highlight preliminary ziftomenib combination data from KOMET-007.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/0001193125-24-016715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524016715/d642740d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-016715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer